- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05522582
Methotrexate Combined With Immunotherapy During Radiotherapy for Solid Tumors
October 3, 2022 updated by: Wei Geng, Yancheng First People's Hospital
Safety and Efficacy of Oral Methotrexate Tablets Combined With Immunotherapy During Radiotherapy for Unresectable/Metastatic Solid Tumors: a Single-center, Prospective Study
Immune checkpoint inhibitors, such as programmed death 1 (PD-1) and programmed cell death-Ligand 1 (PD-L1), offer new approaches for systemic treatment of tumors, but clinical efficacy remains limited.
Previous studies by our team have found that methotrexate can activate anti-tumor immunity.
The discovery of a new effect of this drug will improve tumor response to immunotherapy and prognosis of patients.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Malignant tumor is a systemic and complex disease that seriously endangers human health, surgery is the preferred treatment for solid tumors.
Due to the extensive invasion and metastasis of advanced tumors, radiotherapy and chemotherapy are the main treatment options.
However, the tolerance of tumor to chemoradiotherapy often leads to treatment failure and poor prognosis.
Immunotherapy provides a new approach for the systemic treatment of tumors, but the clinical efficacy is still limited.
Therefore, it is important to find effective drugs to improve the tumor response to radiotherapy and immunotherapy.
Previous studies by our team have found that methotrexate can activate anti-tumor immunity.
The discovery of a new effect of this drug will improve tumor response to immunotherapy and prognosis of patients.
The objective of this clinical trial is to explore the efficacy and safety of methotrexate combined with immunotherapy and radiotherapy in patients with unresectable/recurrence solid tumors.
Study Type
Interventional
Enrollment (Anticipated)
50
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Wei Geng, M.D.
- Phone Number: 86-0515-66696967
- Email: weihuo2001@163.com
Study Contact Backup
- Name: Bei Wang, Ph.D.
- Phone Number: 86-0515-66696817
- Email: yzwangbei@163.com
Study Locations
-
-
Jiangsu
-
Yancheng, Jiangsu, China, 224000
- Recruiting
- Yancheng First People's Hospital
-
Contact:
- Wei Geng, M.D.
- Phone Number: 86-0515-66696967
- Email: weihuo2001@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects have unresectable/ metastatic solid tumors;
- ≥ 18 years old;
- Life expectancy of at least 3 months;
- Eastern Cooperative Oncology Group performance status 0-2;
- Have at least one measurable lesion ≥ 1 cm as defined by response criteria;
- Adequate organ function.
Exclusion Criteria:
- Subjects with a history of autoimmune diseases or syndromes;
- Serious uncontrolled medical disorders or active infections;
- Women who are pregnant or breastfeeding;
- Subjects have other factors that may cause them to terminate the study, such as other serious medical conditions (including mental illness) that require combined treatment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: methotrexate+anti-PD-1 antibody+radiotherapy
Tablets with 5mg methotrexate are taken orally twice a week during radiotherapy.
With anti-PD-1 monoclonal antibody, 200mg, Q3W.
|
Tablets with 5mg methotrexate are taken orally twice a week during the whole course of radiotherapy
Other Names:
Anti-PD-1 monoclonal antibody 200mg is given intravenously every 3 weeks from the first day of radiotherapy until or after the end of treatment.
Other Names:
6~15MV X-ray, 2Gy/time, 5times/week.
The duration of radiotherapy depends on the target lesion.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
Time Frame: Up to 3 months
|
ORR is defined as the percentage of participants in the analysis population who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions)
|
Up to 3 months
|
Treatment-related adverse events (AEs)
Time Frame: Up to 6 months
|
Incidence, nature, and severity of adverse events graded according to the NCI CTCAE v5.0
|
Up to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Numbers of CD3+, CD4+ and CD8+T lymphocyte subsets in peripheral blood detected by flow cytometry
Time Frame: Approximately 2 months
|
Laboratory tests for T-cell detection will be performed before and after treatment.
|
Approximately 2 months
|
Levels of IL-6, TNF-α and IFN-γ in peripheral blood detected by flow cytometry
Time Frame: Approximately 2 months
|
Peripheral blood will be collected before, during and after treatment for laboratory serum cytokine detection.
|
Approximately 2 months
|
Progression-free Survival (PFS) per RECIST 1.1
Time Frame: Up to 12 months
|
PFS is defined as the time from enrollment to the first documented disease progression per RECIST 1.1 based on blinded independent central review or death due to any cause, whichever occurs first.
|
Up to 12 months
|
Overall Survival (OS)
Time Frame: Up to 36 months
|
OS is defined as the time from enrollment to death from any cause during the course of the study.
|
Up to 36 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Wei Geng, M.D., Yancheng First People's Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 15, 2021
Primary Completion (Anticipated)
June 30, 2023
Study Completion (Anticipated)
December 31, 2024
Study Registration Dates
First Submitted
August 28, 2022
First Submitted That Met QC Criteria
August 30, 2022
First Posted (Actual)
August 31, 2022
Study Record Updates
Last Update Posted (Actual)
October 6, 2022
Last Update Submitted That Met QC Criteria
October 3, 2022
Last Verified
October 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Dermatologic Agents
- Reproductive Control Agents
- Abortifacient Agents, Nonsteroidal
- Abortifacient Agents
- Folic Acid Antagonists
- Antibodies
- Antibodies, Monoclonal
- Methotrexate
- Immune Checkpoint Inhibitors
Other Study ID Numbers
- 2021-K-099
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumors
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
National Cancer Institute (NCI)RecruitingSolid Tumor | Refractory Solid Tumors | Malignant Solid Tumors | Other Neoplasms Solid Tumors | Pediatric Solid TumorUnited States
-
Hoffmann-La RocheCompletedSolid Tumors, Advanced Solid TumorsUnited States
-
Esperance Pharmaceuticals IncCompletedAdvanced Solid Tumors | Solid TumorsUnited States
-
Incyte Biosciences Japan GKCompletedAdvanced Solid Tumors | Metastatic Solid TumorsJapan
-
Memorial Sloan Kettering Cancer CenterKyowa Hakko Kirin Pharma, Inc.CompletedAdvanced Solid Tumors | Metastatic Solid TumorsUnited States
-
Bristol-Myers SquibbCompletedAdvanced Solid Tumors | Metastatic Solid TumorsKorea, Republic of, Canada, Australia
-
Cancer Institute and Hospital, Chinese Academy...RecruitingRefractory Solid Tumors | Relapsed Solid TumorsChina
-
Genentech, Inc.RecruitingAdvanced Solid Tumors | Metastatic Solid TumorsCanada, Korea, Republic of, United States, Brazil, Australia, Argentina, Spain, New Zealand, Poland
-
AmgenCompletedCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced MalignancyUnited States, Australia
Clinical Trials on Methotrexate tablets
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.CompletedRheumatoid ArthritisChina
-
University of AlexandriaCompleted
-
University of AlexandriaTerminatedReduction in Pain | Reduction of Inflammation | Improvement in FunctionEgypt
-
Centre of Clinical Pharmacology, Hanoi Medical...Not yet recruitingIrritable Bowel Syndrome With DiarrheaVietnam
-
Cara Therapeutics, Inc.RecruitingPruritus | Notalgia ParestheticaUnited States, Poland, Spain, Canada, Germany
-
Shanghai Zhongshan HospitalRecruitingTakayasu Arteritis | Methotrexate | Inhibition | TreatmentChina
-
Jiangsu vcare pharmaceutical technology co., LTDCompletedInflammatory Bowel DiseasesChina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Not yet recruiting
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Not yet recruitingHematologic MalignancyChina